专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080102121A1 COMPOSITIONS COMPRISING NANOPARTICULATE MELOXICAM AND CONTROLLED RELEASE HYDROCODONE 审中-公开
标题翻译：包含纳米颗粒糊精和受控释放氢化物的组合物
公开(公告)号：US20080102121A1
公开(公告)日：2008-05-01
申请号：US11768169
申请日：2007-06-25
申请人： John G. Devane , Paul Stark , Niall Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G. Devane , Paul Stark , Niall Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/14 , A61K31/485 , A61K9/00 , A61K31/54 , A61P25/00
CPC分类号： A61K31/485 , A61K9/145 , A61K9/146 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/1676 , A61K9/5078 , A61K9/5084 , A61K31/54
摘要： The invention relates to a compositions comprising a nanoparticulate meloxicam composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.
摘要翻译：本发明涉及一种组合物，其包含与多颗粒改性释放氢可酮组合物组合的纳米微粒美洛昔康组合物，其在给予患者时以双峰或多峰方式递送氢可酮。多微粒改性组合物包含第一组分和至少一个后续组分; 所述第一组分包含第一群含氢可酮的颗粒，所述至少一个随后的组分包含第二组含有氢可酮的颗粒，其中所述组分的组合表现出双峰或多峰释放曲线。本发明还涉及包含这种组合组合物的固体口服剂型。

2. 发明申请

US20080113025A1 COMPOSITIONS COMPRISING NANOPARTICULATE NAPROXEN AND CONTROLLED RELEASE HYDROCODONE 审中-公开
标题翻译：包含纳米颗粒纳普罗宁和受控释放氢化物的组合物
公开(公告)号：US20080113025A1
公开(公告)日：2008-05-15
申请号：US11768154
申请日：2007-06-25
申请人： John G. Devane , Paul Stark , Niall Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G. Devane , Paul Stark , Niall Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K31/485 , A61K9/26
CPC分类号： A61K31/485 , A61K9/145 , A61K9/146 , A61K9/5078 , A61K9/5084 , A61K45/06 , A61K2300/00
摘要： The invention relates to a compositions comprising a nanoparticulate naproxen composition in combination with a multiparticulate modified release hydrocodone composition that, upon administration to a patient, delivers a hydrocodone in a bimodal or multimodal manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component; the first component comprising a first population of hydrocodone-comprising particles and the at least one subsequent component comprising a second population of hydrocodone-comprising particles, wherein the combination of the components exhibit a bimodal or multimodal release profile. The invention also relates to a solid oral dosage form comprising such a combination composition.
摘要翻译：本发明涉及包含纳米颗粒萘普生组合物与多微粒改性释放氢可酮组合物组合的组合物，其在施用于患者时以双峰或多峰方式递送氢可酮。多微粒改性组合物包含第一组分和至少一个后续组分; 所述第一组分包含第一群含氢可酮的颗粒，所述至少一个随后的组分包含第二组含有氢可酮的颗粒，其中所述组分的组合表现出双峰或多峰释放曲线。本发明还涉及包含这种组合组合物的固体口服剂型。

3. 发明申请

US20100136106A1 Modified Release Famciclovir Compositions 审中-公开
标题翻译：改性释放泛昔洛韦组合物
公开(公告)号：US20100136106A1
公开(公告)日：2010-06-03
申请号：US11568891
申请日：2006-06-07
申请人： Gary Liversidge , Scott Jenkins , John G. Devane , Paul Stark , Niall Fanning , Gurvinder Singh Rekhi
发明人： Gary Liversidge , Scott Jenkins , John G. Devane , Paul Stark , Niall Fanning , Gurvinder Singh Rekhi
IPC分类号： A61K31/52 , A61K9/48 , A61P31/22 , A61P31/20 , A61K9/58
CPC分类号： A61K9/5078 , A61K9/5026 , A61K9/5084
摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers famciclovir in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition, and to a method for the treatment or suppression of viral infections.
摘要翻译：本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送泛昔洛韦。多微粒改性释放组合物包含第一组分和至少一个后续组分，第一组分包含含有颗粒的第一组活性成分和至少一种随后的组分，其包含第二组含有颗粒的活性成分。本发明还涉及含有这种多微粒改性释放组合物的固体口服剂型，以及用于治疗或抑制病毒感染的方法。

4. 发明申请

US20100247636A1 Nanoparticulate and controlled release compositions comprising nilvadipine 审中-公开
标题翻译：包含尼伐地平的纳米颗粒和控释组合物
公开(公告)号：US20100247636A1
公开(公告)日：2010-09-30
申请号：US11479013
申请日：2006-06-30
申请人： John G. Devane , Paul Stark , Niall M.M. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G. Devane , Paul Stark , Niall M.M. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/48 , A61K31/4422 , A61K9/14 , A61K9/50 , A61K9/26 , A61K9/22 , A61P9/12 , A61P9/00
CPC分类号： A61K9/5026 , A61K9/5047 , A61K9/5084 , A61K31/192 , A61K31/485
摘要： The present invention provides a composition comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, useful in the treatment and prevention of hypertension or related cardiovascular disorders. In one embodiment, the composition comprises nanoparticulate particles comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of hypertension or related cardiovascular disorders.
摘要翻译：本发明提供一种组合物，其包含可用于治疗和预防高血压或相关心血管疾病的尼伐地平或其盐，衍生物，前药或多晶型物。在一个实施方案中，组合物包含包含尼伐地平或其盐，衍生物，前药或多晶型物和至少一种表面稳定剂的纳米颗粒颗粒。纳米颗粒具有小于约2000nm的有效平均粒度。在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送尼伐地平或其盐，衍生物，前药或多晶型物。本发明还涉及含有这种组合物的剂型，以及治疗和预防高血压或相关心血管疾病的方法。

5. 发明申请

US20080279929A1 Nanoparticulate and Controlled Release Compositions Comprising Cefditoren 有权
标题翻译：包含头孢托仑的纳米颗粒和对照释放组合物
公开(公告)号：US20080279929A1
公开(公告)日：2008-11-13
申请号：US11671276
申请日：2007-02-05
申请人： John G. Devane , Paul Stark , Nial M. N. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G. Devane , Paul Stark , Nial M. N. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/52 , A61K31/546 , A61K9/14 , A61K9/20 , A61K9/48 , A61P31/00 , A61K9/00
CPC分类号： A61K9/5084
摘要： The present invention provides a composition comprising a cefditoren, or a salt, derivative, prodrug, or other form thereof, for example, cefditoren pivoxil, useful in the treatment and prevention of infections and related conditions. The invention provides a composition which comprises nanoparticulate particles comprising the cefditoren, or a salt, derivative, prodrug, or other form thereof and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a cefditoren, or a salt, derivative, prodrug, or other form thereof, or nanoparticles comprising the same, in a pulsatile or continuous manner.
摘要翻译：本发明提供一种组合物，其包含可用于治疗和预防感染和相关病症的头孢托仑或其盐，衍生物，前药或其他形式，例如匹戊头孢托仑。本发明提供一种组合物，其包含包含头孢托仑或其盐，衍生物，前药或其它形式的纳米颗粒颗粒和至少一种表面稳定剂。纳米颗粒具有小于约2000nm的有效平均粒度。本发明还提供以脉动或连续方式递送头孢托仑或其盐衍生物，前药或其它形式或包含其的纳米颗粒的组合物。

6. 发明申请

US20110008435A1 Nanoparticulate and Controlled Release Compositions Comprising Aryl-Heterocyclic Compounds 审中-公开
标题翻译：包含芳基杂环化合物的纳米微粒和控制释放组合物
公开(公告)号：US20110008435A1
公开(公告)日：2011-01-13
申请号：US11672263
申请日：2007-02-07
申请人： John G. Devane , Paul Stark , Niall M.M. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
发明人： John G. Devane , Paul Stark , Niall M.M. Fanning , Gurvinder Singh Rekhi , Scott A. Jenkins , Gary Liversidge
IPC分类号： A61K9/14 , A61K31/496 , A61P25/18
CPC分类号： A61K9/5084
摘要： The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers ziprasidone in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of schizophrenia and similar psychiatric disorders.
摘要翻译：本发明提供一种包含齐拉西酮的组合物，其可用于治疗和预防精神分裂症和类似的精神障碍。在一个实施方案中，组合物包含包含齐拉西酮和至少一种表面稳定剂的纳米颗粒颗粒。纳米颗粒具有小于约2000nm的有效平均粒度。在另一个实施方案中，组合物包含改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送齐拉西酮。本发明还涉及含有这些组合物的剂型，以及治疗和预防精神分裂症和类似精神障碍的方法。

7. 发明申请

US20080118556A1 Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone 审中-公开
标题翻译：包含卡比多巴，左旋多巴和恩他卡朋组合的组合物的改良释放
公开(公告)号：US20080118556A1
公开(公告)日：2008-05-22
申请号：US11422226
申请日：2006-06-05
申请人： John G. Devane , Paul Stark , Niall M. M. Fanning , Gurvinder Singh Rekhi , Gary Liversidge , Scott A. Jenkins
发明人： John G. Devane , Paul Stark , Niall M. M. Fanning , Gurvinder Singh Rekhi , Gary Liversidge , Scott A. Jenkins
IPC分类号： A61K31/195 , A61K9/14 , A61K9/20 , A61K9/48 , A61P25/16
CPC分类号： A61K31/195 , A61K9/1676 , A61K9/5078 , A61K9/5084 , A61K31/275 , A61K2300/00
摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers a combination of carbidopa, levodopa and entacapone in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition, and to a method for the treatment of Parkinson's disease.
摘要翻译：本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送卡比多巴，左旋多巴和恩他卡朋的组合。多微粒改性释放组合物包含第一组分和至少一个后续组分，第一组分包含含有颗粒的第一组活性成分和至少一种随后的组分，其包含第二组含有颗粒的活性成分。本发明还涉及含有这种多微粒释放组合物的固体口服剂型，以及治疗帕金森病的方法。

8. 发明申请

US20110064803A1 NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2 审中-公开
标题翻译：包含维生素K2的纳米颗粒和受控释放组合物
公开(公告)号：US20110064803A1
公开(公告)日：2011-03-17
申请号：US11569206
申请日：2006-05-09
申请人： John G. Devane , Paul Stark , Niall M.N. Fanning , Gurvinder Singh Rekhi , Gary Liversidge , Scott Jenkins
发明人： John G. Devane , Paul Stark , Niall M.N. Fanning , Gurvinder Singh Rekhi , Gary Liversidge , Scott Jenkins
IPC分类号： A61K9/64 , A61K9/14 , A61K31/122 , A61K9/20 , A61K9/22 , A61K9/48 , A61K9/54 , A61K9/50 , A61P19/10
CPC分类号： A61K9/5026 , A61K9/5047 , A61K9/5084
摘要： The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of osteoporosis. The invention also relates to a controlled release composition comprising a vitamin K2 or a nanoparticulate vitamin K2 that in operation delivers the drug in a pulsed or multi-modal manner for the prevention and treatment of osteoporosis.
摘要翻译：本发明涉及包含具有改善的生物利用度的纳米颗粒维生素K2的组合物。组合物的纳米颗粒维生素K2颗粒具有小于约2000nm的有效平均粒度，并且可用于预防和治疗骨质疏松症。本发明还涉及包含维生素K2或纳米颗粒维生素K2的控释组合物，其在操作中以脉冲或多模式递送药物以预防和治疗骨质疏松症。

9. 发明申请

US20090297597A1 Modified Release Ticlopidine Compositions 审中-公开
标题翻译：改良释放噻氯匹定组合物
公开(公告)号：US20090297597A1
公开(公告)日：2009-12-03
申请号：US11569481
申请日：2006-06-09
申请人： Gary Liversidge , Scott Jenkins , Paul Stark , Niall M.N. Fanning , Gurvinder Singh Rekhi , John G. Devane
发明人： Gary Liversidge , Scott Jenkins , Paul Stark , Niall M.N. Fanning , Gurvinder Singh Rekhi , John G. Devane
IPC分类号： A61K9/48 , A61K9/00 , A61K9/14 , A61K31/4365 , A61K9/58 , A61K9/60 , A61P43/00
CPC分类号： A61K9/5026 , A61K9/5047 , A61K9/5084 , A61K31/192 , A61K31/485
摘要： The invention relates to a multiparticulate modified release composition that, upon administration to a patient, delivers ticlopidine in a bimodal, multimodal or continuous manner. The multiparticulate modified release composition comprises a first component and at least one subsequent component, the first component comprising a first population of active ingredient containing particles and the at least one subsequent component comprising a second population of active ingredient containing particles. The invention also relates to a solid oral dosage form containing such multiparticulate modified release composition, and to methods for inhibiting platelet aggregation, inhibiting blood clotting, and reducing risk of stroke in a patient.
摘要翻译：本发明涉及一种多微粒改性释放组合物，其在给予患者时以双峰，多峰或连续方式递送噻氯匹定。多微粒改性释放组合物包含第一组分和至少一个后续组分，第一组分包含含有颗粒的第一组活性成分和至少一种随后的组分，其包含第二组含有颗粒的活性成分。本发明还涉及含有这种多微粒释放组合物的固体口服剂型，以及用于抑制血小板聚集，抑制血液凝固和降低患者中风风险的方法。

10. 发明授权

US06902742B2 Multiparticulate modified release composition 有权
标题翻译：多微粒改性组合物
公开(公告)号：US06902742B2
公开(公告)日：2005-06-07
申请号：US10331754
申请日：2002-12-30
申请人： John G. Devane , Paul Stark , Niall M. M. Fanning , Gurvinder Singh Rekhi
发明人： John G. Devane , Paul Stark , Niall M. M. Fanning , Gurvinder Singh Rekhi
IPC分类号： A61K9/26 , A61K9/20 , A61K9/40 , A61K9/48 , A61K9/50 , A61K9/54 , A61K9/56 , A61K9/58 , A61K31/4458 , A61K47/32 , A61P11/00 , A61P25/00 , A61P43/00 , A61K9/14
CPC分类号： A61K9/5084
摘要： The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component comprising a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency.
摘要翻译：本发明涉及一种多微粒改性释放组合物，其在操作中以脉冲或双峰方式递送活性成分。多微粒改性释放组合物包含立即释放组分和改性释放组分; 所述立即释放组分包含含有颗粒的第一组活性成分，所述改性释放组分包含第二组活性成分，所述活性成分含有涂覆有控释涂层的颗粒; 其中操作中的速释组分和改进释放组分的组合以脉冲或双峰方式递送活性成分。本发明还涉及含有这种多微粒改性释放组合物的固体口服剂型。通过多微粒改性释放组合物实现的血浆曲线有利于减少患者对活性成分的耐受性，并通过降低剂量频率提高患者依从性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式